MedTrace Logo

Effect of Type of General Anesthesia Maintenance on Exhaled Nitric Oxide and Eosinophil Blood Count

NCT02065635 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-02-01

No results posted yet for this study

Summary

* Nitric oxide (NO) is a free radical in gas state which plays an important role in a variety of processes relevant to respiratory physiology. It represents a means of detecting airway hyperresponsiveness and appears to have a strong correlation with the eosinophilic infiltration of the airway. Patients who suffered bronchospasm or laryngospasm intraoperatively or postoperatively showed higher levels of exhaled NO.
* Propofol modifies NO production by stimulating the constitutive synthesis of NO and by inhibiting the inducible production of NO. It seems to exert protective effects on acute lung injury (ALI) in experimental models and it can possibly reduce exhaled NO. There is also evidence that some intravenous anesthetic agents can influence chemotaxis of eosinophils in vitro.
* Variation of exhaled NO and eosinophils in surgical patients undergoing anesthesia has not been studied before. Therefore, the aim of this study will be to investigate the differential impact of maintenance of general anesthesia with propofol versus maintenance with sevoflurane on exhaled NO and eosinophil blood count.

Conditions

  • Anesthesia
  • Exhaled Nitric Oxide
  • Eosinophil Blood Count

Interventions

PROCEDURE

maintenance with sevoflurane

in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane

PROCEDURE

maintenance with propofol

in patients allocated to the propofol group, general anesthesia will be maintained with propofol

Sponsors & Collaborators

  • Aretaieion University Hospital

    lead OTHER

Principal Investigators

  • Kassiani Theodoraki, PhD, DEAA · Aretaieion University Hospital

  • Artemis Vekrakou, MD · Aretaieion University Hospital

  • Eriphylli Argyra, PhD · Aretaieion University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02065635 on ClinicalTrials.gov